Literature DB >> 25489833

The business case for cell and gene therapies.

Mohamed Abou-El-Enein1, Gerhard Bauer2, Petra Reinke1.   

Abstract

Mesh：

Year:  2014        PMID： 25489833     DOI： 10.1038/nbt.3084

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  9 in total

1.  Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement.

Authors:  Peter J Neumann; James D Chambers; Françoise Simon; Lisa M Meckley
Journal:  Health Aff (Millwood)       Date:  2011-12       Impact factor: 6.301

2.  Chinese gene therapy. Gendicine's efficacy: hard to translate.

Authors:  Hao Xin
Journal:  Science       Date:  2006-11-24       Impact factor: 47.728

3.  Pharmaceutical risk-sharing agreements.

Authors:  Joseph P Cook; John A Vernon; Richard Manning
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

4.  Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union.

Authors:  Seppo Ylä-Herttuala
Journal:  Mol Ther       Date:  2012-10       Impact factor: 11.454

5.  Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.

Authors:  Eric Faulkner; Lieven Annemans; Lou Garrison; Mark Helfand; Anke-Peggy Holtorf; John Hornberger; Dyfrig Hughes; Tracy Li; Daniel Malone; Katherine Payne; Uwe Siebert; Adrian Towse; David Veenstra; John Watkins
Journal:  Value Health       Date:  2012-09-07       Impact factor: 5.725

6.  Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs.

Authors:  Mohamed Abou-El-Enein; Andy Römhild; Daniel Kaiser; Carola Beier; Gerhard Bauer; Hans-Dieter Volk; Petra Reinke
Journal:  Cytotherapy       Date:  2013-03       Impact factor: 5.414

7.  The special case of gene therapy pricing.

Authors:  Troyen A Brennan; James M Wilson
Journal:  Nat Biotechnol       Date:  2014-09       Impact factor: 54.908

Review 8.  A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV.

Authors:  Mohamed Abou-El-Enein; Gerhard Bauer; Petra Reinke; Matthias Renner; Christian K Schneider
Journal:  Trends Mol Med       Date:  2014-09-25       Impact factor: 11.951

9.  Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans.

Authors:  Fabio Candotti; Kit L Shaw; Linda Muul; Denise Carbonaro; Robert Sokolic; Christopher Choi; Shepherd H Schurman; Elizabeth Garabedian; Chimene Kesserwan; G Jayashree Jagadeesh; Pei-Yu Fu; Eric Gschweng; Aaron Cooper; John F Tisdale; Kenneth I Weinberg; Gay M Crooks; Neena Kapoor; Ami Shah; Hisham Abdel-Azim; Xiao-Jin Yu; Monika Smogorzewska; Alan S Wayne; Howard M Rosenblatt; Carla M Davis; Celine Hanson; Radha G Rishi; Xiaoyan Wang; David Gjertson; Otto O Yang; Arumugam Balamurugan; Gerhard Bauer; Joanna A Ireland; Barbara C Engel; Gregory M Podsakoff; Michael S Hershfield; R Michael Blaese; Robertson Parkman; Donald B Kohn
Journal:  Blood       Date:  2012-09-11       Impact factor: 22.113
  9 in total
  11 in total

1.  Glybera's second act: the curtain rises on the high cost of therapy.

Authors:  Seppo Ylä-Herttuala
Journal:  Mol Ther       Date:  2015-02       Impact factor: 11.454

2.  Registry Contributions to Strengthen Cell and Gene Therapeutic Evidence.

Authors:  Mohamed Abou-El-Enein; David W Grainger; Sven Kili
Journal:  Mol Ther       Date:  2018-04-21       Impact factor: 11.454

Review 3.  Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line.

Authors:  Diogo Gomes-Silva; Carlos A Ramos
Journal:  Biotechnol J       Date:  2017-10-30       Impact factor: 4.677

4.  Microfluidic Transduction Harnesses Mass Transport Principles to Enhance Gene Transfer Efficiency.

Authors:  Reginald Tran; David R Myers; Gabriela Denning; Jordan E Shields; Allison M Lytle; Hommood Alrowais; Yongzhi Qiu; Yumiko Sakurai; William C Li; Oliver Brand; Joseph M Le Doux; H Trent Spencer; Christopher B Doering; Wilbur A Lam
Journal:  Mol Ther       Date:  2017-07-08       Impact factor: 11.454

5.  Utah's cell sheet tissue engineering center.

Authors:  Kyungsook Kim; David W Grainger; Teruo Okano
Journal:  Regen Ther       Date:  2019-05-10       Impact factor: 3.419

6.  MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy.

Authors:  Guido Moll; Norman Drzeniek; Julian Kamhieh-Milz; Sven Geissler; Hans-Dieter Volk; Petra Reinke
Journal:  Front Immunol       Date:  2020-05-19       Impact factor: 7.561

Review 7.  The role of mesenchymal stromal cells in immune modulation of COVID-19: focus on cytokine storm.

Authors:  Maria Kavianpour; Mahshid Saleh; Javad Verdi
Journal:  Stem Cell Res Ther       Date:  2020-09-18       Impact factor: 6.832

8.  Hurdles to uptake of mesenchymal stem cells and their progenitors in therapeutic products.

Authors:  Peter G Childs; Stuart Reid; Manuel Salmeron-Sanchez; Matthew J Dalby
Journal:  Biochem J       Date:  2020-09-18       Impact factor: 3.857

9.  Manufacturing of dental pulp cell-based products from human third molars: current strategies and future investigations.

Authors:  Maxime Ducret; Hugo Fabre; Olivier Degoul; Gianluigi Atzeni; Colin McGuckin; Nico Forraz; Brigitte Alliot-Licht; Frédéric Mallein-Gerin; Emeline Perrier-Groult; Jean-Christophe Farges
Journal:  Front Physiol       Date:  2015-08-06       Impact factor: 4.566

Review 10.  Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer's disease.

Authors:  Misha Angrist; Anna Yang; Boris Kantor; Ornit Chiba-Falek
Journal:  Life Sci Soc Policy       Date:  2020-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.